ABT-737

Name: ABT-737
Brand: Selleck Chemicals
SKU: S1002
Rating: 5 (299 reviews)

For research use only.

Catalog No.S1002

299 publications

CAS No. 852808-04-9

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.

Selleck's ABT-737 has been cited by 299 publications

Cell, 2018, 175(2):429-441

PubMed: 30245008 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):435-449

PubMed: 29533784 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2013, 19(11):1478-88

PubMed: 24141421 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Adv Biol Regul, 2021, S2212-4926(20)30091-9

PubMed: 33451973 ( click the link to review the publication )

Commun Biol, 2021, 4(1):20

PubMed: 33398046 ( click the link to review the publication )

ACS Nano, 2020, 14(3):3378-3388

PubMed: 32083466 ( click the link to review the publication )

Sci Adv, 2020, 6(47)eabc3465

PubMed: 33208362 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO J, 2020, e105071

PubMed: 32840892 ( click the link to review the publication )

Cancer Res, 2020, 10.1158/0008-5472.CAN-19-1784

PubMed: 32005716 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0756

PubMed: 33334730 ( click the link to review the publication )

Development, 2020, 147(22)dev194555

PubMed: 33028610 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.510.2019

PubMed: 32371581 ( click the link to review the publication )

Allergy Asthma Immunol Res, 2020, 12(4):608-625

PubMed: 32400128 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Mol Biosci, 2020, 7:566291

PubMed: 33425984 ( click the link to review the publication )

Sci Rep, 2020, 20;10(1):687

PubMed: 31959760 ( click the link to review the publication )
Cancer Cell Int, 2020, 20:405

PubMed: 32863764 ( click the link to review the publication )

Biomed Pharmacother, 2020, 126:110040

PubMed: 32145585 ( click the link to review the publication )

Ann Transl Med, 2020, 8(6):364

PubMed: 32355808 ( click the link to review the publication )

Eur J Pharm Sci, 2020, 142:105105

PubMed: 31669390 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038

PubMed: 32015503 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002

PubMed: 32061152 ( click the link to review the publication )

Cell Rep, 2020, 32(1):107845

PubMed: 32640215 ( click the link to review the publication )

Life Sci Alliance, 2020, 28;3(6) pii: e202000735

PubMed: 32345661 ( click the link to review the publication )

Transfusion, 2020, 60(4):806-814

PubMed: 32159862 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Infect Immun, 2020, 10.1128/IAI.00851-19

PubMed: 32179584 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100034

PubMed: 32793892 ( click the link to review the publication )

Cell Death Dis, 2020, 11(1):8

PubMed: 31907357 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5770

PubMed: 31852899 ( click the link to review the publication )

EMBO J, 2019, 15;38(10):e101638

PubMed: 30902848 ( click the link to review the publication )

EMBO J, 2019, 38(11)

PubMed: 30979778 ( click the link to review the publication )

Dev Cell, 2019, 51(2):277-291

PubMed: 31564612 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2339-2351

PubMed: 30862722 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3657-3671

PubMed: 31216482 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Elife, 2019, 8e38730

PubMed: 31042147 ( click the link to review the publication )
Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31540244 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):121

PubMed: 30741926 ( click the link to review the publication )

J Cancer, 2019, 10(6):1466-1478

PubMed: 31031856 ( click the link to review the publication )

Thromb Haemost, 2019, 19(10):1665-1674

PubMed: 31493778 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:5820415

PubMed: 31885804 ( click the link to review the publication )

Eur J Immunol, 2019, 10.1002/eji.201948254

PubMed: 31411729 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Biochem J, 2019, 476(9):1335-1357

PubMed: 30992316 ( click the link to review the publication )

Phytomedicine, 2019, 64:153068

PubMed: 31419729 ( click the link to review the publication )

Phytomedicine, 2019, 52:147-156

PubMed: 30599894 ( click the link to review the publication )

Life Sci, 2019, 232:116561

PubMed: 31247208 ( click the link to review the publication )

Chem Biol Interact, 2019, 309:108723

PubMed: 31228469 ( click the link to review the publication )

J Bone Oncol, 2019, 19:100268

PubMed: 31832331 ( click the link to review the publication )

J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0225977

PubMed: 31826021 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:897-906

PubMed: 30774376 ( click the link to review the publication )

Platelets, 2019, 30(1):75-80

PubMed: 29125379 ( click the link to review the publication )

Oncotarget, 2019, 10(58):6219-6233

PubMed: 31692812 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(1):84-97

PubMed: 30649895 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5435

PubMed: 30575733 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(21):5458-5470

PubMed: 30021909 ( click the link to review the publication )

Cell Death Differ, 2018, 25(4):784-796

PubMed: 29229994 ( click the link to review the publication )

Oncogene, 2018, 37(39):5325-5339

PubMed: 29858601 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):994

PubMed: 30250198 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):199

PubMed: 29415991 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(3):1123-1138

PubMed: 30041196 ( click the link to review the publication )

Eur J Med Chem, 2018, 159:357-380

PubMed: 30308410 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(6):935-946

PubMed: 29545477 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Sci Rep, 2018, 8(1):15752

PubMed: 30361682 ( click the link to review the publication )

Int J Oncol, 2018, 53(3):1055-1068

PubMed: 30015875 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(6):465-474

PubMed: 29394130 ( click the link to review the publication )

Phytother Res, 2018, 32(6):1126-1134

PubMed: 29464855 ( click the link to review the publication )

Thromb Res, 2018, 171:22-30

PubMed: 30240944 ( click the link to review the publication )

Environ Mol Mutagen, 2018, 59(1):49-59

PubMed: 28843007 ( click the link to review the publication )

Ann Surg Treat Res, 2018, 95(5):240-248

PubMed: 30402442 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )
Oncotarget, 2018, 9(42):26834-26851

PubMed: 29928488 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Biomaterials, 2017, 144:73-83

PubMed: 28823845 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 29148970 ( click the link to review the publication )

Oncogene, 2017, 36(15):2066-2073

PubMed: 27694901 ( click the link to review the publication )

Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )

Sci Signal, 2017, 10(499)

PubMed: 28974650 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Eur J Immunol, 2017, 47(6):1009-1021

PubMed: 28493377 ( click the link to review the publication )

Biochem Pharmacol, 2017, 140:41-52

PubMed: 28595877 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15105-15120

PubMed: 28673964 ( click the link to review the publication )

Analyst, 2017, 142(23):4399-4404

PubMed: 29116264 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(3)e00535-16

PubMed: 27821478 ( click the link to review the publication )

Clin Immunol, 2017, 181:32-42

PubMed: 28579554 ( click the link to review the publication )

Toxicol In Vitro, 2017, 42:38-46

PubMed: 28366708 ( click the link to review the publication )

Mol Cell Biochem, 2017, 429(1-2):91-102

PubMed: 28120212 ( click the link to review the publication )

Arch Oral Biol, 2017, 73:1-6

PubMed: 27632413 ( click the link to review the publication )

Oncol Lett, 2017, 14(1):903-908

PubMed: 28693250 ( click the link to review the publication )
Asia Pac J Clin Oncol, 2017, 13(2):e144-e152

PubMed: 26552712 ( click the link to review the publication )

Oncotarget, 2017, 8(65):108522-108533

PubMed: 29312548 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Cell Death Dis, 2017, 8(6):e2898

PubMed: 28661475 ( click the link to review the publication )

Oncotarget, 2017, 8(43):74299-74311

PubMed: 29088786 ( click the link to review the publication )

Anat Rec (Hoboken), 2017, 300(2):326-339

PubMed: 27486855 ( click the link to review the publication )

Thromb Haemost, 2017, 117(2):311-324

PubMed: 27929199 ( click the link to review the publication )

Oncotarget, 2017, 8(29):46801-46817

PubMed: 27086916 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28692422 ( click the link to review the publication )

Oncotarget, 2017, 8(5):8670-8678

PubMed: 28055968 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(5):1138-49

PubMed: 26467384 ( click the link to review the publication )

Br J Pharmacol, 2016, 173(3):471-83

PubMed: 26493374 ( click the link to review the publication )

Cell Death Dis, 2016, 7(8):e2342

PubMed: 27537525 ( click the link to review the publication )

Br J Cancer, 2016, 114(11):1219-26

PubMed: 27140314 ( click the link to review the publication )

Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )

J Virol, 2016, 90(5):2356-71

PubMed: 26676786 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(4):562-71

PubMed: 26704388 ( click the link to review the publication )

Lab Invest, 2016, 96(10):1128-37

PubMed: 27617402 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(6):1345-57

PubMed: 27429848 ( click the link to review the publication )
Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

J Immunother, 2016, 39(3):117-26

PubMed: 26938945 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(4):607-13

PubMed: 27343560 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):143-148

PubMed: 27449608 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Exp Ther Med, 2016, 11(2):669-673

PubMed: 26893664 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83208-83222

PubMed: 27825124 ( click the link to review the publication )

Sci Rep, 2016, 6:21264

PubMed: 26887909 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(51):85492-85501

PubMed: 27863431 ( click the link to review the publication )

Oncotarget, 2016, 7(24):35989-36001

PubMed: 27056884 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79637-79653

PubMed: 27793034 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84594-84607

PubMed: 27829238 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77815-77824

PubMed: 27780925 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Autophagy, 2015, 11(3):452-9

PubMed: 25715028 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(17):3995-4003

PubMed: 26015514 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(6):E536-45

PubMed: 25624498 ( click the link to review the publication )

EMBO Rep, 2015, 16(5):618-27

PubMed: 25739811 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 25432173 ( click the link to review the publication )
Cell Death Differ, 2015, 10.1038/cdd.2015.8

PubMed: 25698446 ( click the link to review the publication )

J Med Chem, 2015, 58(4):1644-68

PubMed: 25585174 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(19):12290-9

PubMed: 25829495 ( click the link to review the publication )

J Biol Chem, 2015, 290(34):20841-55

PubMed: 26124276 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:34

PubMed: 25852302 ( click the link to review the publication )

Neurogastroenterol Motil, 2015, 10.1111/nmo.12521

PubMed: 25690069 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):667-76

PubMed: 25434832 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: 25596561 ( click the link to review the publication )

Exp Cell Res, 2015, 335(1):62-7

PubMed: 26024774 ( click the link to review the publication )

Exp Cell Res, 2015, 10.1016/j.yexcr.2015.04.016

PubMed: 25936772 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

Chembiochem, 2015, 16(5):757-65

PubMed: 25711460 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143685

PubMed: 26606677 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 464(1):286-91

PubMed: 26116776 ( click the link to review the publication )

Exp Hematol, 2015, 43(3):180-190.e6

PubMed: 25461257 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 10.1016/j.mrfmmm.2015.04.005

PubMed: ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(5):334-40

PubMed: 26178811 ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22624-40

PubMed: 26265439 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36338-53

PubMed: 26462148 ( click the link to review the publication )
Oncotarget, 2015, 6(8):5582-96

PubMed: 25714024 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Oncotarget, 2015, 6(1):409-26

PubMed: 25565667 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35667-83

PubMed: 26447615 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Hepatol Res, 2015, 45(9):1023-1033

PubMed: 25297967 ( click the link to review the publication )

Nat Commun, 2014, 5:5637

PubMed: 25472497 ( click the link to review the publication )

Autophagy, 2014, 10(10):1776-86

PubMed: 25126729 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5446-55

PubMed: 25208882 ( click the link to review the publication )

Leukemia, 2014, 28(10):1960-8

PubMed: 24577530 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Biomaterials, 2014, 16(2):R41

PubMed: 24745479 ( click the link to review the publication )

Cell Death Differ, 2014, 21(7):1170-7

PubMed: 24682005 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.158

PubMed: 25301069 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.09.024

PubMed: 25304383 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Biomaterials Science, 2014, 10.1039/C4BM00072B

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1275

PubMed: 24901046 ( click the link to review the publication )

Acta Neuropathol Commun, 2014, 10.1186/2051-5960-2-57

PubMed: 24887326 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-13-0998

PubMed: 24739394 ( click the link to review the publication )

Mol Cancer Res, 2014, 13(12):3332-42

PubMed: 25154561 ( click the link to review the publication )

Mol Cancer Res, 2014, (4):550-9

PubMed: 24469836 ( click the link to review the publication )
J Immunol, 2014, 193(10):4914-23

PubMed: 25288570 ( click the link to review the publication )

Bone, 2014, 67:166-74

PubMed: 25016096 ( click the link to review the publication )

J Biol Chem, 2014, 289(22):15495-15506

PubMed: 24739390 ( click the link to review the publication )

J Immunother, 2014, 37(1):8-15

PubMed: 24316551 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(11):20500-17

PubMed: 25387078 ( click the link to review the publication )

Int J Cardiol, 2014, 176(3):923-9

PubMed: 25194861 ( click the link to review the publication )

Int J Hyperthermia, 2014, 30(7):502-12

PubMed: 25354679 ( click the link to review the publication )

Cell Cycle, 2014, 10.4161/15384101.2014.973321

PubMed: ( click the link to review the publication )

Thromb Res, 2014, 134(6):1311-5

PubMed: 25288466 ( click the link to review the publication )

Thromb Res, 2014, 133(1):73-9

PubMed: 24268298 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84388

PubMed: 24427286 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105049

PubMed: 25126950 ( click the link to review the publication )

PLoS One, 2014, 9(3):e91782

PubMed: 24626299 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96733

PubMed: 24824755 ( click the link to review the publication )

Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:306718

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(11):4321-6

PubMed: 23447565 ( click the link to review the publication )

Mol Cancer, 2013, 12(1):42

PubMed: 23680104 ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

J Neurosci, 2013, 33(46):18098-108

PubMed: 24227720 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e702

PubMed: 23828565 ( click the link to review the publication )
Cell Death Dis, 2013, 4:e762

PubMed: 23928701 ( click the link to review the publication )

Br J Cancer, 2013, 108(9):1870-8

PubMed: 23558901 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e690

PubMed: 23807219 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e801

PubMed: 24030153 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Br J Haematol, 2013, 163(3):377-84

PubMed: 24033315 ( click the link to review the publication )

Br J Haematol, 2013, 161(2):245-54

PubMed: 23398569 ( click the link to review the publication )

Stem Cells Transl Med, 2013, 2(9):690-702

PubMed: 23934910 ( click the link to review the publication )

Cancer Sci, 2013, 104(6):732-9

PubMed: 23421409 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(2):109-21

PubMed: 23233484 ( click the link to review the publication )

Cancer Gene Ther, 2013, 20(7):386-93

PubMed: 23788110 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):6826-34

PubMed: 23329846 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1403-15

PubMed: 23760752 ( click the link to review the publication )

Biomed Pharmacother, 2013, 67(7):583-91

PubMed: 23706691 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 274(2):319-27

PubMed: 24321340 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(5):944-51

PubMed: 23395630 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63232

PubMed: 23658815 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78570

PubMed: 24223823 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 437(4):565-72

PubMed: 23850692 ( click the link to review the publication )

Leuk Lymphoma, 2013, 54(2):372-80

PubMed: 22830613 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2013, 113(3):145-51

PubMed: 23557083 ( click the link to review the publication )

J Ovarian Res, 2013, 6(1):72

PubMed: 24103422 ( click the link to review the publication )

Phys Biol, 2013, 10(3):035002

PubMed: 23735516 ( click the link to review the publication )
Cytometry A, 2013, 83(2):227-34

PubMed: 23165976 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 24334291 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Mol Cell, 2012, 46(5):573-83

PubMed: 22560721 ( click the link to review the publication )

J Clin Invest, 2012, 122(6):2018-31

PubMed: 22622039 ( click the link to review the publication )

EMBO J, 2012, 31(10):2322-35

PubMed: 22510886 ( click the link to review the publication )

Oncogene, 2012, 31(26):3177-89

PubMed: 22056880 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(3):R96

PubMed: 22703841 ( click the link to review the publication )

Anal Chem, 2012, 84(11):4703-10

PubMed: 22533353 ( click the link to review the publication )

Br J Haematol, 2012, 159(5):565-71

PubMed: 23025479 ( click the link to review the publication )

Mol Cancer Res, 2012, 10(3):347-59

PubMed: 22241218 ( click the link to review the publication )

J Biol Chem, 2012, 287(25):21357-70

PubMed: 22553204 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17682-92

PubMed: 22433870 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(9):1508-20

PubMed: 22771494 ( click the link to review the publication )

Phytother Res, 2012, 27(6):835-40

PubMed: 22899281 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

PLoS One, 2012, 7(8):e43158

PubMed: 22912816 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52333

PubMed: 23284992 ( click the link to review the publication )

J Pharmacol Sci, 2012, 119(4):330-40

PubMed: 22814102 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

J Clin Invest, 2011, 121(3):1053-63

PubMed: 21317538 ( click the link to review the publication )

Leukemia, 2011, 25(11):1728-38

PubMed: 21701487 ( click the link to review the publication )

Neuro Oncol, 2011, 13(12):1265-76

PubMed: 21880625 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )
Oncogene, 2011, 30(37):3918-29

PubMed: 21460857 ( click the link to review the publication )

Am J Nephrol, 2011, 34(6):549-59

PubMed: 22123611 ( click the link to review the publication )

Cancer Chemoth Pharm, 2011, 67(3):557-67

PubMed: 20473610 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20423

PubMed: 21674052 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24102

PubMed: 21949692 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Curr Pharmacogenomics Person Med, 2011, 9(3):184-190

PubMed: 22162984 ( click the link to review the publication )

Mol Cancer Ther, 2010, 19(20):5591-601

PubMed: 20587662 ( click the link to review the publication )

J Biol Chem, 2010, 285(26):19910-20

PubMed: 20421300 ( click the link to review the publication )

Apoptosis, 2010, 15(10):1256-69

PubMed: 20582477 ( click the link to review the publication )

Exp Hematol, 2010, 38(10):908-921

PubMed: 20540984 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Features

First-generation inhibitor of anti-apoptotic Bcl-2 proteins.

Targets

Bcl-2 ^[1] (Cell-free assay)	Bcl-xL ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)	Bcl-B ^[1] (Cell-free assay)
30.3 nM(EC50)	78.7 nM(EC50)	197.8 nM(EC50)	1.82 μM(EC50)

In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. ^[1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. ^[2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. ^[3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. ^[4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
OCI-Ly1	NIfTV5RE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXuyOVAhdk4EoB?=	NXTpdm9HPzJiaB?=	MWDEUXNQ	MYHjZZV{\WRiOUelJIxwe3Nib3[geoli[mmuaYT5JIlvKGOnbHzzJJRz[W6\|ZnXjeIVlKHerdHigRmNNPiC\|aWLORS=>	NYfw[JNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVczQDhpPkK2OlU4Ojh6PD;hQi=>
KG1a	Ml7CR4VtdCCYaXHibYxqfHliQYPzZZk>	NUDETZhvOC1zMDFOwG0>	M33FZ\|I1KGh?	MWPEUXNQ	M3fjZWlEPTB;Nz62PEDPxE1uIHTlZ5Jm[XOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NEj0U\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW1NlcyOid-Mk[1OVI4OTJ:L3G+
Kasumi-1	Mn21R4VtdCCYaXHibYxqfHliQYPzZZk>	NHLudYgxNTFyIN88US=>	Mki2NlQhcA>?	M3XWdmROW09?	MV3JR\|UxRTRwOEeg{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NEPEdGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW1NlcyOid-Mk[1OVI4OTJ:L3G+
KG1a	MmLxRZBweHSxc3nzJGF{e2G7	Mn35NE0yOCEQvF2=	MXOyOEBp	NV7KdWZ{TE2VTx?=	MYDpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MnLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NUK3NVIoRjJ4NUWyO\|EzRC:jPh?=
Kasumi-1	NV:x[WZISXCxcITvd4l{KEG\|c3H5	M1\SXVAuOTBizszN	MkX1NlQhcA>?	M3\XcWROW09?	NVex[XhrcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV3MkexNkc,OjZ3NUK3NVI9N2F-
MC-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHKOU8yOC9{MDFOwG0>	M3jZZVI1KGh?	NE\PVnNFVVOR	MnPubY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M1rGWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NES3OlE2Lz5{NkS0O\|YyPTxxYU6=
HN22	MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;veJMzNjVxNz61M\|IzNjVizszN	NX7VVVh7OjRiaB?=	NHrabXpFVVOR	MoHCbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NFGyfno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS0O\|YyPSd-Mk[0OFc3OTV:L3G+
MC-3	MWDBdI9xfG:\|aYOgRZN{[Xl?	NWfpfGxuPS9zMD:yNEDPxE1?	M1LLPVI1KGh?	M1PiTWROW09?	NH7DVlNqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz	NVrKOIVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0OFc3OTVpPkK2OFQ4PjF3PD;hQi=>
HN22	MXfBdI9xfG:\|aYOgRZN{[Xl?	MoDqNk42NzdwNT:yNk42KM7:TR?=	MWWyOEBp	MmrnSG1UVw>?	MnjZbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?=	M3nQ[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NES3OlE2Lz5{NkS0O\|YyPTxxYU6=
MOLT-4	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml32NVAuPTByMDDuUS=>	Mom2O\|IhcA>?	MW\EUXNQ	MWnJR\|UxRTBwMUm4JO69VQ>?	NGfUTWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5NlM{Oid-Mk[zPVI{OzJ:L3G+
RS4;11	NFr1d5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrSeZR[OTBvNUCwNEBvVQ>?	M33IbVczKGh?	MYjEUXNQ	M4XNfGlEPTB;MD6wNFIh\|ryP	M4KwVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{myN\|MzLz5{NkO5NlM{OjxxYU6=
JURKAT	MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvZWW4yOC13MECwJI5O	MmnsO\|IhcA>?	MXzEUXNQ	NFOyeoVKSzVyPU[2JO69VQ>?	NH75ZZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5NlM{Oid-Mk[zPVI{OzJ:L3G+
CEM R	NGPwfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVKxNE02ODByIH7N	NGj3NoY4OiCq	MWTEUXNQ	NUjjSJBmUUN3ME21MlQh\|ryP	NX\V[pl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVI{OzJpPkK2N\|kzOzN{PD;hQi=>
CEM S	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfSbFNFOTBvNUCwNEBvVQ>?	NYjwZ2E{PzJiaB?=	NYDGS5ZyTE2VTx?=	NInIdmhKSzVyPUGyMlEh\|ryP	NVvoW2U4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVI{OzJpPkK2N\|kzOzN{PD;hQi=>
MOLT-4	M3XwbGFxd3C2b4Ppd{BCe3OjeR?=	Mn\KNVAuOTByMDDuUS=>	M{DmflI1KGh?	MVHEUXNQ	MX7jZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?=	NVGxZYRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVI{OzJpPkK2N\|kzOzN{PD;hQi=>
CEM S	MVfBdI9xfG:\|aYOgRZN{[Xl?	MUOxNE0yODByIH7N	MlTmNlQhcA>?	M4D2OGROW09?	NE\LSGlk[XW\|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=>	MlvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUKzN\|IoRjJ4M{myN\|MzRC:jPh?=
JURKAT	MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWKxNFAuOTByMDDuUS=>	MYq0PEBp	M3npOWROW09?	M3zUVWlEPTB;OUW1xtE6NjNibl2=	NGTWfG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG3NlI3QSd-Mk[xO\|IzPjl:L3G+
LOUCY	MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnBb2k3OTByLUGwNFAhdk1?	MXe0PEBp	MYDEUXNQ	MnTaTWM2OD1\|Mj64xtEyOC57IH7N	NFLKbnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG3NlI3QSd-Mk[xO\|IzPjl:L3G+
WM-115	NWDqdVVvS2WubDDWbYFjcWyrdImgRZN{[Xl?	MYexNFDDqG6P	NIG0bFk4OiCq		M4i5WYVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2\|dYL2bZZidMLi	Mlu2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMU[3O\|YoRjJ4MUG2O\|c3RC:jPh?=
B16	NUTUVpFbS2WubDDWbYFjcWyrdImgRZN{[Xl?	NUPFXpBlOTBywrDuUS=>	M3HLVFczKGh?		MWflcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNke3Okc,OjZzMU[3O\|Y9N2F-
HL-60	NIHvXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX\tdmpoPzJiaB?=		NXr2SlA{UUN3MNMgQUAyOC55IH7N	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2NU[wPUc,OjZyNEW2NFk9N2F-
MOLM-13	M1;ld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWLEZ2FGPzJiaB?=		Mny0TWM2OMLiPTCyO{46KG6P	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2NU[wPUc,OjZyNEW2NFk9N2F-
OCI-AML3	MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{L6PFczKGh?		NUX6Zoo5UUN3MNMgQUAyQTVyIH7N	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2NU[wPUc,OjZyNEW2NFk9N2F-
BCWM.1	NHr3eY5CeG:ydH;zbZMhSXO\|YYm=	MV6wMVEvPiEQvF2=	NH3PPWgzPCCq		MljEbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M3zMRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEmzNlkxLz5{NUi5N\|I6ODxxYU6=
MWCL-1	MlHxRZBweHSxc3nzJGF{e2G7	NYjBOmFbOC1zLk[g{txO	M4DsXVI1KGh?		M2TFfYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NGHQUlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi5N\|I6OCd-MkW4PVMzQTB:L3G+
MM.1s	MnLNRZBweHSxc3nzJGF{e2G7	MVewMVEvPiEQvF2=	M17TPVI1KGh?		Mmn6bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh7M{K5NEc,OjV6OUOyPVA9N2F-
HCT116	MorVSpVv[3Srb36gRZN{[Xl?	MYGzM\|ExKM7:TR?=	MlfFNVLDqGkEoB?=	Mm\qSG1UVw>?	MVzpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK\|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNUCyPEc,OjV5MUWwNlg9N2F-
HCT116 BAX BAK1 DKO	MY\GeY5kfGmxbjDBd5NigQ>?	NHX5TXY{NzFyIN88US=>	NVH5VI1oOTMEoHlCpC=>	NWLlbIxXTE2VTx?=	MnvHbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w	M{HafVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{G1NFI5Lz5{NUexOVAzQDxxYU6=
HCT116	M3zBXmZ2dmO2aX;uJGF{e2G7	NYTxSWtkOTBizszN	NVW3PJhwOTMEoHlCpC=>	MX;EUXNQ	NG[2bIZqdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th	MlTmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MUWwNlgoRjJ3N{G1NFI5RC:jPh?=
HCT116 BAX BAK1 DKO	M4G3[2Z2dmO2aX;uJGF{e2G7	MoCwNVAh\|ryP	M372ZlEzyqCqwrC=	NGLF[lJFVVOR	M{Hjcolv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNUCyPEc,OjV5MUWwNlg9N2F-
HCT116	M4rVTWF2fG:yaHHnfUBCe3OjeR?=	MYixNEDPxE1?	NYTnTFRoOTMEoHlCpC=>	MkDLSG1UVw>?	M2WzN4lv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNUCyPEc,OjV5MUWwNlg9N2F-
HCT116 BAX BAK1 DKO	Moq2RZV1d3CqYXf5JGF{e2G7	MnK5NVAh\|ryP	M2\Z[FEzyqCqwrC=	NHu1TIxFVVOR	NVHWTohpcW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V?	NHf3cXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexOVAzQCd-MkW3NVUxOjh:L3G+
U937	M4XpTGFxd3C2b4Ppd{BCe3OjeR?=	M{X3WVAvOTJ3LUKg{txO	NXfpSWNsOjRiaB?=		NGf1PHhmdmijbnPld{BFUEFxWD2xNU1qdmS3Y3XkJIFxd3C2b4Ppdy=>	NHnCb\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexOFAzPCd-MkW3NVQxOjR:L3G+
U937	M1n4V2Fxd3C2b4Ppd{BCe3OjeR?=	M4r3R\|AvPSEQvF2=	NHLIOHczPCCq		NHi1SlZmdmijbnPld{BkdGWjdnHn[UBw\iCSQWLQJIFv\CClYYPwZZNmNTNiYYOge4VtdCCjczDOc5hiKGyndnXs	NVPVOnp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVQxOjRpPkK1O\|E1ODJ2PD;hQi=>
HL-60 AAA-Bcl-2	NXzINZl4SXCxcITvd4l{KEG\|c3H5	MmLLNE02KM7:TR?=	M4DRelQ5KGh?		NH7vfnlKSzVyPUCuPFch\|ryv78{MbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M2rvc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{GxOFYxLz5{NUexNVQ3ODxxYU6=
HL-60 EEE-Bcl-2	NFSwOVRCeG:ydH;zbZMhSXO\|YYm=	NGewUVYxNTVizszN	NHL0NIk1QCCq		NEfETG1KSzVyPUWg{txu97zOIHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NIG2UXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexNVQ3OCd-MkW3NVE1PjB:L3G+
U87	M1;Ue2Z2dmO2aX;uJGF{e2G7	MX21NEDPxE1?	Mn7tNlQhcA>?		M2H4e5Jm\HWlZYOgeIhmKG2UTlGg[ZhxemW\|c3nvckBt\X[nbIOgc4YhVU2SLUKsJG1OWC1zNDDhcoQhSmOuLUK=	NFPEcJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[2O\|Y3Oyd-MkW2Olc3PjN:L3G+
K562	MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmLCNU0yOCEQvF2=	Mo\COFghcA>?	MlzISG1UVw>?	MmTrTWM2OD1{Nj63JO69VQ>?	NEfoeFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5OlU3OSd-MkW1PVY2PjF:L3G+
K562/Mcl -1-IRESBim	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIP5TlFKSzVyPUmuN{DPxE1?	M{j1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO1PVAxLz5{NUWzOVkxODxxYU6=
K562/Bcl- 2-IRESBim	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPJ[pJFUUN3ME2wMlM2KM7:TR?=	NXrPZldmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
Jurkat	Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPvRmZKSzVyPUCuOlYh\|ryP	NVrNZmpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
JurkatΔBak	NHWxXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDvW5JKSzVyPkWwJO69VQ>?	Mn63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
HL60/VCR	MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rEW2lEPTB-MUCwJO69VQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|NUmwNEc,OjV3M{W5NFA9N2F-
Kasumi-1	MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvn[WhOUUN3ME2wMlAyKM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|NUmwNEc,OjV3M{W5NFA9N2F-
Kasumi-1/ABT	NFTxPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlS3TWM2OD1yLkWxJO69VQ>?	MmG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
THP-1	NUTXTnR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTFwMkeg{txO	NEWycGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
U937	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\CTWM2OD13LkK5JO69VQ>?	M{W4UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO1PVAxLz5{NUWzOVkxODxxYU6=
C1498	NXvqTY5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTZwMUOg{txO	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|NUmwNEc,OjV3M{W5NFA9N2F-
RPMI 8226	NEfRcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3v1S2lEPTB;MD6yOUDPxE1?	MlvRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
MM.1S	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTBwNECg{txO	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|NUmwNEc,OjV3M{W5NFA9N2F-
NCI-H929	NHnDXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLPcmRKSzVyPUG1MlIyKM7:TR?=	Mlf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
U266	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PtZWlEPTB;MD62PEDPxE1?	MnHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
MCF-7	NF;QfnpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NF;tZXA2KM7:TR?=	NWXaSmZXPDhiaB?=	M{\hRWROW09?	MUHlcohidmOnczD0bIUhe2Wwc3n0bZZqfHlidH:gc5IhemGmaXH0bY9v	MnG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEmxNlQoRjJ3NEC5NVI1RC:jPh?=
MCF-7	Mlq3RZBweHSxc3nzJGF{e2G7	MkewOUDPxE1?	MWi0M\|I1NzR6IHi=	MkjkSG1UVw>?	M2nyc4lv[3KnYYPld{B1cGViY3zlZZZm\CCSQWLQ	M1m3OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEC5NVI1Lz5{NUSwPVEzPDxxYU6=
MCF-7	MVTGeY5kfGmxbjDBd5NigQ>?	M2G1NFUh\|ryP	M4fWWFI1KGh?	MWLEUXNQ	NUS2VVZC\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRyOUGyOEc,OjV2MEmxNlQ9N2F-
MDA-MB 231	NELPWWlHfW6ldHnvckBCe3OjeR?=	MkHLOUDPxE1?	Ml7QNlQhcA>?	MYPEUXNQ	M3LQZYVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>?	NXvCVG1{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NFkyOjRpPkK1OFA6OTJ2PD;hQi=>
ZR-75-1	MnHpSpVv[3Srb36gRZN{[Xl?	NGPvVog2KM7:TR?=	M4[5OFI1KGh?	NFq5RoJFVVOR	MVjlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO\|aX;uxsA>	NUnVOYlIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NFkyOjRpPkK1OFA6OTJ2PD;hQi=>
A549	M{nYXmNmdGxiVnnhZoltcXS7IFHzd4F6	NFH1WWkxNTJyIN88US=>	MVe3NkBp	MmPQSG1UVw>?	M2PpTIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	M{nafVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{i4O\|YzLz5{NUO4PFc3OjxxYU6=
H1299	NGXvfG5E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFfDU\|YxNTJyIN88US=>	MoPFO\|IhcA>?	MkXJSG1UVw>?	MofK[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	M1\hR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{i4O\|YzLz5{NUO4PFc3OjxxYU6=
HO-8910	NEHp[4NE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MUCwMVIxKM7:TR?=	M{TIU\|czKGh?	NXzBPZlnTE2VTx?=	NEDhRnpl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	NGjo[II9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO4PFc3Oid-MkWzPFg4PjJ:L3G+
HT-29	NIfQcm9E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	Mn[xNE0zOCEQvF2=	NVf4T2xxPzJiaB?=	NUnHS482TE2VTx?=	NFXzXIZl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	NWHJWHljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
HCT-116	MnLiR4VtdCCYaXHibYxqfHliQYPzZZk>	MUWwMVIxKM7:TR?=	MnvFO\|IhcA>?	NWjmZ2lXTE2VTx?=	Mn3r[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	NHzZcZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO4PFc3Oid-MkWzPFg4PjJ:L3G+
A549	MWnBdI9xfG:\|aYOgRZN{[Xl?	MmTZNlAh\|ryP	MV60PEBp	NUP3SY5tTE2VTx?=	MYDpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	NHvUbZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO4PFc3Oid-MkWzPFg4PjJ:L3G+
H1299	NXvmbnNUSXCxcITvd4l{KEG\|c3H5	NWPhS5h5OjBizszN	MW[0PEBp	NFHzSVhFVVOR	Mn\ibY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6=	NXO1THU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
Sc-1	NH\2RmtE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NHHNW3QxNjByMEGtNUDPxE1?	MVu5OkBp		NIG1O2Zl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NUTjO4E3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO\|M2ODhpPkK1N\|c{PTB6PD;hQi=>
OcI-LY18	MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MYOwMlAxODFvMTFOwG0>	NYW1R3RiQTZiaB?=		NWDUTIZ1\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M1z3SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{ezOVA5Lz5{NUO3N\|UxQDxxYU6=
RL	M{TMNmNmdGxiVnnhZoltcXS7IFHzd4F6	MW[wMlAxODFvMTFOwG0>	MUm5OkBp		NULHNI1E\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M{PkV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{ezOVA5Lz5{NUO3N\|UxQDxxYU6=
RKO	NHuye4RE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3;mV\|AuOTBizszN	NYrUVZJ[OjUkgJnoxsA>	MU\EUXNQ	NH3XWYRKSzVyPvMAjVI26oDLwsXN	NHT2Smo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwOFM5Oyd-MkWzNFQ{QDN:L3G+
Caco-2	Mlv1R4VtdCCYaXHibYxqfHliQYPzZZk>	NUG5WW86OC1zMDFOwG0>	M1m5UlI16oDLaNMg	NE\sbmpFVVOR	M1:5R2lEPTB;MUmuO-KBkcL3TR?=	M3vs[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C0N\|g{Lz5{NUOwOFM5OzxxYU6=
DLD1	M4jlfGNmdGxiVnnhZoltcXS7IFHzd4F6	NWLYWVN1OC1zMDFOwG0>	MYKyOQKBkWkEoB?=	NX7BUYU{TE2VTx?=	MorQTWM2OD1zOD63PQKBkcL3TR?=	NX22NYFpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFQ{QDNpPkK1N\|A1Ozh\|PD;hQi=>
LS411N	MkKwR4VtdCCYaXHibYxqfHliQYPzZZk>	MUGwMVExKM7:TR?=	NX[zRpBNOjUkgJnoxsA>	MYTEUXNQ	M1XzemlEPTB;MUGuOFfjiIoEtV2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyNEO4N{c,OjV\|MESzPFM9N2F-
SW620	NIPodVBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NV;JdGFTOC1zMDFOwG0>	NY\BdHVlOjUkgJnoxsA>	NYryU5JJTE2VTx?=	NE\uOoJKSzVyPUGyMlI16oDLwsXN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyNEO4N{c,OjV\|MESzPFM9N2F-
HCT116	NFO5N3RE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MkDwNE0yOCEQvF2=	NF\2PFIzPOLCiXlCpC=>	NIHRb2lFVVOR	M4PwZmlEPTB;MkCuOFnjiIoEtV2=	MnLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MESzPFMoRjJ3M{C0N\|g{RC:jPh?=
HaCaT	M4qxR2NmdGxiVnnhZoltcXS7IFHzd4F6	MWiwMlEwOS9zMDFOwG0>	MW[yOEBp	Ml\WSG1UVw>?	M3W2ZYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M3HOXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkGwO\|k2Lz5{NUKxNFc6PTxxYU6=
A5-RT3	MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MlXINE4yNzFxMUCg{txO	NFrXdIkzPCCq	NXXwTXN1TE2VTx?=	Mnr3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M{PGOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkGwO\|k2Lz5{NUKxNFc6PTxxYU6=
HaCaT	NXv6UXJ4TnWwY4Tpc44hSXO\|YYm=	M4fhZlEx6oDLzszN	NYLqcGpjOjRxNEigbC=>	NVG0VFk{TE2VTx?=	M3zHTIlv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?=	M3HzVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkGwO\|k2Lz5{NUKxNFc6PTxxYU6=
A5-RT3	NUPubGNuTnWwY4Tpc44hSXO\|YYm=	NGTNO5UyOOLCid88US=>	MVeyOE81QCCq	M{nuNmROW09?	MV;pcoR2[2W\|IF3NVEBidmRiRF7BJIZz[WevZX70ZZRqd25?	NYHW[XJzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVA4QTVpPkK1NlExPzl3PD;hQi=>
A5-RT3	NX7vWmd4TnWwY4Tpc44hSXO\|YYm=	NGTRRVk2KM7:TR?=	MVS2JIg>	MYDEUXNQ	MV\pcoR2[2W\|IITo[UBz\WynYYPlJI9nKG2rdH;jbI9v\HKrYXygdJJwfGWrboOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yC\|dYL2bZZidCCrbjDhJINie3Cjc3WtbY5l\XCnbnTlcpQhdWGwbnXy	MmjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MUC3PVUoRjJ3MkGwO\|k2RC:jPh?=
U266	M37X[mZ2dmO2aX;uJGF{e2G7	MUO1NFAwPzVyIH7N	NIjCOFMzPC92ODDo	NWjINZgzTE2VTx?=	NGG2R\|Zld3ewcnXneYxifGW\|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm\|b3\vdo0>	NHfGcFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwPFg5QCd-MkWyNFg5QDh:L3G+
RPMI8226	NX;vZm9VTnWwY4Tpc44hSXO\|YYm=	NE\EWHM2ODBxN{WwJI5O	MoXjNlQwPDhiaB?=	MXvEUXNQ	NWKxRWlE\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyOEi4PEc,OjV{MEi4PFg9N2F-
MM.1S	NGHYUm9HfW6ldHnvckBCe3OjeR?=	M1;aUFUxOC95NUCgcm0>	NU\hOoNNOjRxNEigbC=>	MVTEUXNQ	NEnnR\|Rld3ewcnXneYxifGW\|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm\|b3\vdo0>	NYPnSoJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFg5QDhpPkK1NlA5QDh6PD;hQi=>
Clone A	NVfGdXlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYSwMlLjiJN4MDFOwG0>	MkCwO\|IhcA>?	MmfMSG1UVw>?	NUjoPHg1UUN3ME23MlUh\|ryP	M{DteFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC4PFgzLz5{NUKwPFg5OjxxYU6=
CX-1	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvSO4sxNjMkgKO2NEDPxE1?	M3jzNFczKGh?	MV;EUXNQ	NEXpdZFKSzVyPUGuPEDPxE1?	M2XrcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC4PFgzLz5{NUKwPFg5OjxxYU6=
LS174T	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV:wMlLjiJN4MDFOwG0>	Mki4O\|IhcA>?	NFTGVlRFVVOR	NH61R4lKSzVyPUG4MlMh\|ryP	NEDROFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwPFg5Oid-MkWyNFg5QDJ:L3G+
HT29	MX;BdI9xfG:\|aYOgRZN{[Xl?	NFTUc44yNzVxMUCg{txO	NFqwTYU1QCCq		NU\PNIdD[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF7MkG4PEc,OjVzOUKxPFg9N2F-
SW480	NX;ROoxMSXCxcITvd4l{KEG\|c3H5	MUGxM\|UwOTBizszN	MXW0PEBp		NH[1Z5Bk[XW\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NEi5OG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG5NlE5QCd-MkWxPVIyQDh:L3G+
Colo205	NEfyb4JCeG:ydH;zbZMhSXO\|YYm=	MVyxM\|UwOTBizszN	MWW0PEBp		MnHGZ4F2e2W\|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF7MkG4PEc,OjVzOUKxPFg9N2F-
Caco2	MmHLRZBweHSxc3nzJGF{e2G7	NXvMfFl2OS93L{GwJO69VQ>?	NXXiS5plPDhiaB?=		MojuZ4F2e2W\|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NV;vNGlTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxPVIyQDhpPkK1NVkzOTh6PD;hQi=>
PCI-13	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFHpXno4OiCq	NUfM[Wo4TE2VTx?=	NVLn[nlxT0l3ME2xOUDDuSBzLkig{txO	Mnj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPFcoRjJ3MUO5N\|g4RC:jPh?=
PCI-15B	NFzVT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH;idYs4OiCq	M3XWNmROW09?	M4LSO2dKPTB;MUGgxtEhPC53IN88US=>	M3jRNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N\|g4Lz5{NUGzPVM5PzxxYU6=
UM-SCC22B	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXK3NkBp	NWPxOmpRTE2VTx?=	NYHTV2d[T0l3ME2xPUDDuSB{Lkmg{txO	NVHMZmQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN\|k{QDdpPkK1NVM6Ozh5PD;hQi=>
UM-SCC47	M3vCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{jjSVczKGh?	Mnj6SG1UVw>?	MX\HTVUxRTF7INMxJFEzNjNizszN	NFjmTFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGzPVM5Pyd-MkWxN\|k{QDd:L3G+
93-VU-147T	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVO3NkBp	MUfEUXNQ	NVS5TY0{T0l3ME20MlMhyrFiMz61JO69VQ>?	M2PrOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N\|g4Lz5{NUGzPVM5PzxxYU6=
UD-SCC2	NGDGcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Moj4O\|IhcA>?	M{f1bWROW09?	NIX1WpZIUTVyPUK4JOKyKDJwOTFOwG0>	NXHKO5pYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN\|k{QDdpPkK1NVM6Ozh5PD;hQi=>
UPCI:SCC90	M1PMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXK3NkBp	MmPBSG1UVw>?	NV65NW9XT0l3ME22MlYhyrFiMT61JO69VQ>?	M2DZfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N\|g4Lz5{NUGzPVM5PzxxYU6=
RPMI-8226	MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NYDBTlc5OTJ3L{K1NE82ODBibl2=	MoH4OFhpyqB?	MXLEUXNQ	NUnuV282\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	Ml;KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEiyNFIoRjJ3MEC4NlAzRC:jPh?=
OPM-2	MmjkR4VtdCCYaXHibYxqfHliQYPzZZk>	NVjwUoZKOTJ3L{K1NE82ODBibl2=	MX[0PIjDqA>?	NEPaPWFFVVOR	MUfk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOEKwNkc,OjVyMEiyNFI9N2F-
RPMI-8226	MnzURZBweHSxc3nzJGF{e2G7	M3\ufVEzPS9{NUCvOVAxKG6P	NFfJb2s1QGkEoB?=	MWLEUXNQ	MYrpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NW\QN3FpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFgzODJpPkK1NFA5OjB{PD;hQi=>
OPM-2	NV\0dHRLSXCxcITvd4l{KEG\|c3H5	NXXRS5lSOTJ3L{K1NE82ODBibl2=	M{LDcVQ5cMLi	NEThO3ZFVVOR	M2\Zcolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M2PzdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC4NlAzLz5{NUCwPFIxOjxxYU6=
COG-LL-319	MYnGeY5kfGmxbjDBd5NigQ>?	MlPUNVAxKG6P	NF\MUmgyNzNxNjDo	MUDEUXNQ	M1jmOolv\HWlZYOgZ4F{eGG\|ZT3k[ZBmdmSnboSgUYNtNTFiY3zlZZZi\2V?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3MUS3Nkc,OjR7NUG0O\|I9N2F-
RS4;11	NXOxOGZwTnWwY4Tpc44hSXO\|YYm=	MWKxNFAhdk1?	NYjlZVk1OS9\|L{[gbC=>	MUfEUXNQ	NVO1OIFScW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?=	M2nVXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUWxOFczLz5{NEm1NVQ4OjxxYU6=
FL5.12	NGnoRWhHfW6ldHnvckBie3OjeR?=				M{fVTXJmfmW{c3HsJI9nKGO7dH;rbY5mKHerdHjkdoF4[WxicILveIVkfGmxbjDpckBKVDNiZHXw[Y5l\W62IFLjcFIhd3[ncnX4dJJme3OrbnegcY92e2ViRly1MlEzKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIHLveolv\SCpZXzheIlvNCCHQ{WwJF0hOC5yMEig{txONg>?	NHmxSGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
DoHH2	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NVnCS2Y2UW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBqdiCqdX3hckBFd0iKMjDj[YxteyCxdnXy[ZhxemW\|c3nu[{BD[2x{IHnuJJBz\XOnbnPlJI9nKDNnIF\CV{whTUN3MDC9JFAvODB6MzFOwG0v	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
RS11380	NWDORZJvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NUnOSoV6UW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBqdiCqdX3hckBTWzFzM{iwJINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEKlbEKgbY4heHKnc3XuZ4Uhd2ZiMzWgSmJUNCCHQ{WwJF0hOC5yMUSg{txONg>?	NVjUfZlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOVY5OzRpPkG3NlU3QDN2PD;hQi=>
FL5.12	NIHkWmdHfW6ldHnvckBie3OjeR?=				M4DFZXJmfmW{c3HsJI9nKGO7dH;rbY5mKHerdHjkdoF4[WxicILveIVkfGmxbjDpckBKVDNiZHXw[Y5l\W62IFLjcE15VCCxdnXy[ZhxemW\|c3nu[{Bud3W\|ZTDGUFUvOTJiY3XscJMhcW5icILld4Vv[2Vib3[gZo93cW6nIHflcIF1cW5uIFXDOVAhRSByLkCzJO69VS5?	NGTRTFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
FL5.12	NI[w[o1HfW6ldHnvckBie3OjeR?=				MmTEVoV3\XK\|YXygc4Yh[3m2b3vpcoUhf2m2aHTyZZdidCCycn;0[YN1cW:wIHnuJGlNOyCmZYDlcoRmdnRiQnPsNkBwfmW{ZYjwdoV{e2mwZzDtc5V{\SCITEWuNVIh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMzWgSmJUNCCHQ{WwJF0hOC5yNTFOwG0v	M4TvfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW2PFM1Lz5zN{K1Olg{PDxxYU6=
DoHH2	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				Mn3kTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDpckBpfW2jbjDEc2hJOiClZXzsd{BwfmW{ZYjwdoV{e2mwZzDCZ4wzKGmwIIDy[ZNmdmOnIH;mJFExLSCKUzygSWM2OCB;IECuNVMh\|ryPLh?=	NYjXeWhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOVY5OzRpPkG3NlU3QDN2PD;hQi=>
RS11380	NFXiNXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MW\Jcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHnuJIh2dWGwIGLTNVE{QDBiY3XscJMhd3[ncnX4dJJme3OrbnegRoNtOiCrbjDwdoV{\W6lZTDv[kAyOCViSGOsJGVEPTBiPTCwMlE2KM7:TT6=	M4e5VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW2PFM1Lz5zN{K1Olg{PDxxYU6=
SUDHL4	NX\5XoNrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NV\sZmZzUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBqdiCqdX3hckBUXUSKTESgZ4VtdHNib4\ldoV5eHKnc4PpcochSmOuMjDpckBxemW\|ZX7j[UBw\iB\|JTDGRnMtKEWFNUCgQUAxNjJ{IN88UU4>	NIP5PFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
FL5.12	NWjmWpd2TnWwY4Tpc44h[XO\|YYm=				NX:xcms2WmW4ZYLzZYwhd2ZiY4n0c4tqdmVid3n0bIRz[XejbDDwdo91\WO2aX;uJIlvKEmOMzDk[ZBmdmSnboSgRoNtNXiOIH;2[ZJmgHC{ZYPzbY5oKG2xdYPlJGZNPS5zMjDj[YxteyCrbjDwdoV{\W6lZTDv[kA{LSCIQmOsJGVEPTBiPTCwMlIzKM7:TT6=	M2r5Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW2PFM1Lz5zN{K1Olg{PDxxYU6=
SUDHL4	NYjNfG9qT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NHHkd4pKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlvKGi3bXHuJHNWTEiONDDj[YxteyCxdnXy[ZhxemW\|c3nu[{BD[2x{IHnuJJBz\XOnbnPlJI9nKDFyJTDIV{whTUN3MDC9JFAvQDVizszNMi=>	NYTqS2xTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOVY5OzRpPkG3NlU3QDN2PD;hQi=>
FL5.12	NV7SW\|NrS3m2b4TvfIlkcXS7IHHzd4F6		NFLUSoczPCCqcoO=		NFnyT5FEgXSxdH;4bYNqfHliYXfhbY5{fCCLTEOt[IVx\W6mZX70JI1wfXOnIF\MOU4yOiClZXzsd{BwfmW{ZYjwdoV{e2mwZzDoeY1idiCEY3yyJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEK0JIhzeyCkeTDNWHMh[XO\|YYmgbY4h[WK\|ZX7j[UBw\iC\|ZYL1cUwhTUN3MDC9JFAvODB5NzFOwG0v	M3nqOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OESxPFgzLz5zOEi0NVg5OjxxYU6=
FL5.12	Mk\IR5l1d3SxeHnjbZR6KGG\|c3H5		M{ftPFI1KGi{cx?=		MlvvR5l1d3SxeHnjbZR6KGGpYXnud5QhUUx\|LXTldIVv\GWwdDDtc5V{\SCITEWuNVIh[2WubIOgc5ZmemW6cILld5NqdmdiaIXtZY4hSmOuLWjMJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEK0JIhzeyCkeTDNWHMh[XO\|YYmgbY4h[WK\|ZX7j[UBw\iC\|ZYL1cUwhTUN3MDC9JFAvODNizszNMi=>	M3XEfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OESxPFgzLz5zOEi0NVg5OjxxYU6=
NCI-H146	NVnVWmxKS3m2b4TvfIlkcXS7IHHzd4F6		MYi0PEBpenN?		MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF2NjDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgbY4heHKnc3XuZ4Uhd2ZiMUClJIh2dWGwIIPldpVuNCCHQ{WwJF0hOC5yOEeg{txONg>?	NWPNVWNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4OFE5QDJpPkG4PFQyQDh{PD;hQi=>
CLL	NEfsfldCeG:ydH;zbZMh[XO\|YYm=				NV:zWolYUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDDUGwh[2WubIOsJGVEPTBiPTCwMlAxPDVizszNMi=>	M{e4NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUK1OFM{Lz5{MEmyOVQ{OzxxYU6=
MEF	NYThUmhkS3m2b4TvfIlkcXS7IHHzd4F6		M3mwNFI1KGi{cx?=		NYX6fZltS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhdWOuLUGg[IVncWOrZX70JG1GTiClZXzsd{Bi\nSncjCyOEBpenNiYomgR4VtdCC2aYTldkBodG9iYYPzZZkhcW5icILld4Vv[2Vib3[gNUUhe2W{dX2sJGVEPTBiPTCwMlAxOjB\|IN88UU4>	NHvORWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO2OlI6PSd-MkGzOlYzQTV:L3G+
MEF	MU\DfZRwfG:6aXPpeJkh[XO\|YYm=		NX35cndUOjRiaILz		NUHmNmQ2S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhdWOuLUGg[IVncWOrZX70JG1GTiClZXzsd{Bi\nSncjCyOEBpenNiYomgR4VtdCC2aYTldkBodG9iYYPzZZkhcW5icILld4Vv[2Vib3[gNVAmKHOncoXtMEBGSzVyIE2gNE4xPTFizszNMi=>	NUji[JEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzOlYzQTVpPkKxN\|Y3Ojl3PD;hQi=>
MEF	NVjSRW1jS3m2b4TvfIlkcXS7IHHzd4F6		MoDsNlQhcHK\|		MmPuR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgcYNtNTFiZHXmbYNq\W62IF3FSkBk\WyuczDh[pRmeiB{NDDodpMh[nliQ3XscEB1cXSncjDncI8h[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiMUClJIZmfGGuIHLveolv\SC\|ZYL1cUwhTUN3MDC9JFAvODVzIN88UU4>	NFHBUWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO2OlI6PSd-MkGzOlYzQTV:L3G+
RS4:11	NGPPS4FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				NWD3WW1CSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSV\|Q7OTFiY3XscJMhcW5icILld4Vv[2Vib3[gNVAmKGi3bXHuJJNmenWvLDDFR\|UxKD1iMD6wNlQh\|ryPLh?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl{NkK0O{c,Ojh7Mk[yOFc9N2F-
MOLT4	MYLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				NEmzS2ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUHQ1KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEGwKUBpfW2jbjDz[ZJ2dSxiRVO1NEA:KDBwNkKyJO69VS5?	NXTHeppERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5NlYzPDdpPkK4PVI3OjR5PD;hQi=>
Jurkat	NGruOVdEgXSxdH;4bYNqfHliYYPzZZk>		NF3qUoc1QCCqcoO=		MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDKeZJs[XRiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JINmdGxidHn0[ZIu[my3ZTDhd5NigSxiSVO1NEA:KDFwM{ig{txONg>?	NWHFdnZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
HCT116	M4HXe2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MWG0PEBpenN?		Mk\pR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFQ5KGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVAhRSB2LkC2JO69VS5?	NGm0NII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0N\|g2QCd-MUm3OFM5PTh:L3G+
SU-8686	NVzZbGVGS3m2b4TvfIlkcXS7IHHzd4F6		NEDiXVk1QCCqcoO=		NHT0Z2pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXS16Nki2JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO\|YYmsJGlEPTBiPTC0MlI1KM7:TT6=	NWG0eG5PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
H460	NHHtS\|dEgXSxdH;4bYNqfHliYYPzZZk>		M2TaUVQ5KGi{cx?=		MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEmFNUCgQUA5NjB\|IN88UU4>	Mm\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEO4OVgoRjF7N{SzPFU5RC:jPh?=
Hepa-1c1c7	M3zkdWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1zGeVQ5KGi{cx?=		NIrHb4VEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBJ\XCjLUHjNYM4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEmFNUCgQUA5NjZ6IN88UU4>	NIHrXXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0N\|g2QCd-MUm3OFM5PTh:L3G+
MCF7	NILvS2NEgXSxdH;4bYNqfHliYYPzZZk>		MWC0PEBpenN?		M2HwN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JINmdGxidHn0[ZIu[my3ZTDhd5NigSxiSVO1NEA:KDJzLkK2JO69VS5?	NVHIdI14RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
DU145	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=		NWnES\|l{PDhiaILz		M37McmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVAhRSB{Nz62JO69VS5?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2M{i1PEc,OTl5NEO4OVg9N2F-
HCT116	MoTFR5l1d3SxeHnjbZR6KGG\|c3H5		M3G1PVczKGi{cx?=		M2Pke2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCneIDy[ZN{cW6pIFLjcE15VCxiQnPsMVIh[W6mIF3jcE0yKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA1Py55IN88UU4>	NFPmc3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG3NlcxOSd-MkKxO\|I4ODF:L3G+
BL21 (DE3)	M4P1TmZ2dmO2aX;uJIF{e2G7		MoDiNkBpenN?		M1[5[mJqdmSrbnegZYZncW6rdImgeI8hVi22ZYLtbY52eyB4WDDIbZMufGGpZ3XkJIh2dWGwIFLjcFIh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUApTEV\|KTDj[YxteyCjZoTldkAzKGi{czDifUBndHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7LDDJR\|UxKD1iMD6wNFIh\|ryPLh?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR2OEm4PEc,OjJ2NEi5PFg9N2F-
BL21 (DE3)	NHG1WndHfW6ldHnvckBie3OjeR?=		MlTWNkBpenN?		NWDqOnZtSmmwZHnu[{Bi\m[rbnn0fUB1dyCQLYTldo1qdnW\|IEjYJGhqey22YXfn[YQhcHWvYX6gRoNtNXiOIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{kh[2WubIOgZYZ1\XJiMjDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhUUN3MDC9JFAvODB4IN88UU4>	M{PRU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NES4PVg5Lz5{MkS0PFk5QDxxYU6=
NCI-H146	MnTJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHLrcmY1KGSjeYO=		MVPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDF2NjDj[YxteyCjZoTldkA1KGSjeYOgZpkhX1OWODDhd5NigSxiSVO1NEA:KDBwMEm3JO69VS5?	NVjRNGpHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OFg6QDhpPkKyOFQ5QTh6PD;hQi=>
NCI-H1417	Mne2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHHVdpI1KGSjeYO=		MnjhS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUhzNEG3JINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6xN{DPxE1w	NVTsNZh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OFg6QDhpPkKyOFQ5QTh6PD;hQi=>
CCRF-CEM	NV\uOXRuS3m2b4TvfIlkcXS7IHHzd4F6		MmnsOFghcHK\|		M{\2OGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNEWkZvQ1XNJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSClZXzseIl1\XJvYnz1[UBie3OjeTygTWM2OCB;IECuO\|Qh\|ryPLh?=	MmLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3OEK5PVEoRjJ{NUiyPVkyRC:jPh?=
HL60	M1vyU2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MnruOFghcHK\|		NV36NmZYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkh[2WubITpeIVzNWKudXWgZZN{[XluIFnDOVAhRSByLke2JO69VS5?	M2LyOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUiyPVkyLz5{MkW4Nlk6OTxxYU6=
K562	NX7LOVk3S3m2b4TvfIlkcXS7IHHzd4F6		MmDIOFghcHK\|		MoDYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT\|U3OiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgZ4VtdHSrdHXyMYJtfWViYYPzZZktKEmFNUCgQUA{PC55IN88UU4>	MkXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3OEK5PVEoRjJ{NUiyPVkyRC:jPh?=
NCI-H146	NGP4WJBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MknkOEBl[Xm\|		NInad5RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTR4IHPlcIx{KGGodHXyJFQh\GG7czDifUBYW1R6IHHzd4F6NCCLQ{WwJF0hOC5yM{eg{txONg>?	NETCXFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0O\|U6QCd-MkK3OFc2QTh:L3G+
NCI-H1963	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIHFdJY1KGSjeYO=		MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3INVk3OyClZXzsd{Bi\nSncjC0JIRigXNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvODV7IN88UU4>	MoDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NEe1PVgoRjJ{N{S3OVk5RC:jPh?=
NCI-H1417	NY\MZ4kzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NID6W\|I1KGSjeYO=		NWDVUXhzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF2MUegZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KFeVVEigZZN{[XluIFnDOVAhRSByLkSxNkDPxE1w	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd2N{W5PEc,OjJ5NEe1PVg9N2F-
RS4:11	MYnBdI9xfG:\|aYOgZZN{[Xl?		M3S5PFQ5KGi{cx?=		MX3JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIFLjcFIh\GWyZX7k[Y51KGi3bXHuJHJUPDpzMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhSW6wZYjpckBXKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7LDDJR\|UxKD1iMD6yO{DPxE1w	NFPLO3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxOFA2PCd-MkOzNVQxPTR:L3G+
K562	MVvBdI9xfG:\|aYOgZZN{[Xl?		NV3wbVJ6PDhiaILz		MWDJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIF3jcFEh\GWyZX7k[Y51KGi3bXHuJGs2PjJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JGFvdmW6aX6gWkB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgSxiSVO1NEA:KDF4LkSg{txONg>?	MkflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUSwOVQoRjJ\|M{G0NFU1RC:jPh?=
NCI-H1963	NFnVUplEgXSxdH;4bYNqfHliYYPzZZk>		M2\P[FQh\GG7cx?=		M4PDcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUm2N{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC0JIRigXNiYomgW3NVKGG\|c3H5MEBKSzVyIE2gNE4xPTRizszNMi=>	NEe3TmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI6QCd-MkO0OFgzQTh:L3G+
NCI-H187	NV\YbnFXS3m2b4TvfIlkcXS7IHHzd4F6		NXO5OHJ3PCCmYYnz		NXm5NINYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVixPFch[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOEBl[Xm\|IHL5JHdUXCCjc4PhfUwhUUN3MDC9JFAvOTN5NzFOwG0v	NIjOflU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI6QCd-MkO0OFgzQTh:L3G+
NCI-H1417	NWn0[po3S3m2b4TvfIlkcXS7IHHzd4F6		M321clQh\GG7cx?=		MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF2MUegZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNDDkZZl{KGK7IGfTWEBie3OjeTygTWM2OCB;IECuNVc{PCEQvF2u	NH;tdGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI6QCd-MkO0OFgzQTh:L3G+
HL60	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1LDWVczKGi{cx?=		NGKyZlRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjl5IN88UU4>	M1vzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{GyPVM6Lz5{N{exNlk{QTxxYU6=
MCF7	M33CVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVH4bZIzPzJiaILz		NXHYbVA1T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOjVwM{Og{txONg>?	NXj6bYtmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3NVI6OzlpPkK3O\|EzQTN7PD;hQi=>
U266	Mk\6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmDPO\|IhcHK\|		MXfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDVNlY3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyO{4{PSEQvF2u	M4TKTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{GyPVM6Lz5{N{exNlk{QTxxYU6=
SKOV3	M{jId2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV\6T49JPzJiaILz		NVLQTZdNT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDR4LkW5JO69VS5?	MlKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MUK5N\|koRjJ5N{GyPVM6RC:jPh?=
RS4:11	MlvKR5l1d3SxeHnjbZR6KGG\|c3H5		M37V[\|I1KGi{cx?=		MnTPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVnM1QjFzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6zN{DPxE1w	Mom3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUOxN\|UoRjJ7NEWzNVM2RC:jPh?=
Remb1	NVXZWVByS3m2b4TvfIlkcXS7IHHzd4F6		NVLSUWIzOjRiaILz		MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDS[Y1jOSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwNDFOwG0v	NHTqO4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1N\|E{PSd-Mkm0OVMyOzV:L3G+
BL21	NEXTR49HfW6ldHnvckBie3OjeR?=	MV2xNEB2VQ>?	NHzpZ\|c{KGi{cx?=		M2LMO2Rqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgS\|E6PkFibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjByMTFOwG0v	M1rC[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	NFy5dnFHfW6ldHnvckBie3OjeR?=	NXm3fW9oOTBidV2=	Mnn1N{BpenN?		NES4Zm5FcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJGE6O1ZibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjByMUSg{txONg>?	NEHqN2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	NETZV\|JHfW6ldHnvckBie3OjeR?=	M3\IWlExKHWP	MVuzJIhzew>?		Mnf2SIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDZNVk2TiCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvODBzNTFOwG0v	MoDSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	MVLGeY5kfGmxbjDhd5NigQ>?	NXL6coFNOTBidV2=	MYezJIhzew>?		NYCwZnhsTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDXbYxlKHS7cHWgRoNtNTJvbHnr[UBxem:2ZXnuJFEh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvODB\|NDFOwG0v	NX30UVhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	NESxW2xHfW6ldHnvckBie3OjeR?=	MUOxNEB2VQ>?	NXHPS4tUOyCqcoO=		NHW5T4pFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJGUyOjmKIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5yMES1JO69VS5?	Mn3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	M{SyUGZ2dmO2aX;uJIF{e2G7	NYXtT4RUOTBidV2=	MmLiN{BpenN?		MXXEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIFW5OmchdXW2YX70JIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOyCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBkd22yZYTpeIlwdiCjc4PhfUwhU2liPTCwMlAxPThizszNMi=>	NVfFOld3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	MlXjSpVv[3Srb36gZZN{[Xl?	M4TnVVExKHWP	NES2Omw{KGi{cx?=		M1L2cmRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgRVE1OkemZXz0ZVE{PlRibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjBzIN88UU4>	MmX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	MnXYSpVv[3Srb36gZZN{[Xl?	M170elExKHWP	NHi3dXA{KGi{cx?=		NV7rbolFTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBCOTR{RzDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMEKxJO69VS5?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyN{WxNkc,OjF6MEe1NVI9N2F-
BL21	MWrGeY5kfGmxbjDhd5NigQ>?	MoTyNVAhfU1?	MXKzJIhzew>?		NIC3eVdFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJGwyOzCYIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5yNUig{txONg>?	MofPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	NU\IVHVTTnWwY4Tpc44h[XO\|YYm=	NFXE[FMyOCC3TR?=	NVziTVF[OyCqcoO=		MmLhSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDk[Yx1[TF\|NmSgcZV1[W62IHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiY3XscJMh[XRiMUCgeW0h[W[2ZYKgN{BpenNiYomg[ox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDjc41x\XSrdHnvckBie3OjeTygT4khRSByLkC2JO69VS5?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyN{WxNkc,OjF6MEe1NVI9N2F-
BL21	NGXRVFRHfW6ldHnvckBie3OjeR?=	NUXiVnNMOTBidV2=	MlyzN{BpenN?		MUHEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIFyxN\|BCKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4xPzNizszNMi=>	NHX6Umc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	NILTepVHfW6ldHnvckBie3OjeR?=	M{e1PFExKHWP	MoDyN{BpenN?		M{W2PWRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgVlExOEVibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjF4IN88UU4>	MmTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	MYHGeY5kfGmxbjDhd5NigQ>?	M1;DfVExKHWP	M3;UUFMhcHK\|		Mo\xSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDWNVQySSCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvOTlizszNMi=>	NHHLWHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	M3njOWZ2dmO2aX;uJIF{e2G7	MmO2NVAhfU1?	NXfiOI5nOyCqcoO=		NGLoV5ZFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJGEyPDKWIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5{NzFOwG0v	NHf5NVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	NHrNcFJHfW6ldHnvckBie3OjeR?=	NVTyfHE3OTBidV2=	NETXPXk{KGi{cx?=		M{K5ZWRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgUFE{OEdibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjJ7IN88UU4>	MoLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	NFzJdldHfW6ldHnvckBie3OjeR?=	NYnSSlJwOTBidV2=	NXnX[5VKOyCqcoO=		NHf5[JFFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJGY6P1ZibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjNizszNMi=>	NU[0cpJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	MkPNSpVv[3Srb36gZZN{[Xl?	NYH4[Jg3OTBidV2=	MXKzJIhzew>?		MmPYSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDZNVAyUCCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvOzhizszNMi=>	M4jTN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21 (DE3)	NIrNdHhHfW6ldHnvckBie3OjeR?=		NYfse5J5OiCqcoO=		M3[5NmJqdmSrbnegZYZncW6rdImgeI8hVi22ZYLtbY52eyB4WDDIbZMufGGpZ3XkJIh2dWGwIFLjcFIh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUApTEV\|KTDj[YxteyCjZoTldkAzKGi{czDifUBndHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7LDDLbUA:KDBwMECwOkDPxE1w	M1HUWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NES4PVg5Lz5{MkS0PFk5QDxxYU6=
BL21 (DE3)	MWfGeY5kfGmxbjDhd5NigQ>?		NV:1UIM{OiCqcoO=		NEHNfnBDcW6maX7nJIFn\mmwaYT5JJRwKE5vdHXycYlvfXNiOGigTIl{NXSjZ3fl[EBpfW2jbjDCZ4wugExiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSBqRFWzLUBk\WyuczDh[pRmeiB{IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBMcSB;IECuNFAyKM7:TT6=	M{fvXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NES4PVg5Lz5{MkS0PFk5QDxxYU6=
Toledo	MYLBdI9xfG:\|aYOgZZN{[Xl?				MVvJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFSxbHXkc{Bk\WyuczygUGQ2OCB;IECuNFYh\|ryPLh?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyME[1Nkc,OjR7MEC2OVI9N2F-
KB	NWOzNFJPS3m2b4TvfIlkcXS7IHHzd4F6	NHnnfocxNjVidV2=			NEjHcnhEgXSxdH;4bYNqfHliaX6gbJVu[W5ic3nSUmEudWWmaXH0[YQuVUOOMT3rcoNwcyCmb4fuJGtDKGOnbHzzJI93\XKneIDy[ZN{cW6pIFLDUFIh[XRiMD61JJVO	NFO2OVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC0NFA1Oyd-MUiwOFAxPDN:L3G+
Eu-Myc	Mmq4RZBweHSxc3nzJIF{e2G7	NVn1XIZIOSC3TR?=			Mmf4TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDtc5V{\SCHdT3NfYMh[2WubIOgc5ZmemW6cILld5NqdmdiQlPMNkBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINwdG:weTDmc5Ju[XSrb36gZZQhOSC3TR?=	NFfCNmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC0NFA1Oyd-MUiwOFAxPDN:L3G+
HeLa	MoLtSpVv[3Srb36gZZN{[Xl?	MVWxJJVO	NELWdFQyOiCqcoO=		MUTJcoR2[3Srb36gc4YhSmOuLYjMMY1m\GmjdHXkJIFxd3C2b4Ppd{BqdiCmb4j5Z5lkdGmwLYP0bY12dGG2ZXSgbJVu[W5iSHXMZUBk\WyuczDveoVz\XiycnXzd4lv\yCQb4jhJIF1KDFidV2gZYZ1\XJiMUKgbJJ{KGK7IFjv[YNpe3Ric4ThbY5qdmd?	M1nHcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{i2PVgzLz5{MkO4Olk5OjxxYU6=
HeLa	NWezcppsTnWwY4Tpc44h[XO\|YYm=	NX;Gd4lDOTBidV2=	NXfZWndpOTZiaILz		M2fSTmlvcGmkaYTpc44hd2ZiUnz1Z{1D[XhxZWnGVE1D[2xveFygbY51\XKjY4Tpc44h\XiycnXzd4VlKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOTZiaILzJIJ6KEKURWSgZZN{[Xl?	NILabW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSyOVA{OSd-MkK0NlUxOzF:L3G+
MDA-MB-231	MV7GeY5kfGmxbjDhd5NigQ>?	M13MW\|AvODNidH:gNUB2VQ>?	NHjiU\|EyKGi{		MUfBcpRi\2:waYP0JIFkfGm4aYT5JIF1KHKnY3;tZolv[W62IFLjcE1ZVCCjc4Pld5Nm\CCjczDy[ZN1d3KjdHnvckBw\iCESV2gRmg{NWmwZIXj[YQhW22jYzDwdo91\WmwIILlcIVie2ViaX6gcYl1d2Oqb37kdoliKGm\|b3zheIVlKG[{b32gUWRCNU2ELUKzNUBk\WyuczDheEAxNjB\|IITvJFEhfU1iYX\0[ZIhOSCqcjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	M2PKPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{S3OVk5Lz5{Mke0O\|U6QDxxYU6=
MDA-MB-231	NEHLT\|ZHfW6ldHnvckBie3OjeR?=	M1;wUVAvODNidH:gNUB2VQ>?	M3nUNFEhcHJ?		MXPBcpRi\2:waYP0JIFkfGm4aYT5JIF1KHKnY3;tZolv[W62IFLjcE1ZVCCjc4Pld5Nm\CCjczDy[ZN1d3KjdHnvckBw\iCESV2gRmg{NWmwZIXj[YQh[3m2b3Podo9u\SClIILlcIVie2ViaX6gcYl1d2Oqb37kdoliKGm\|b3zheIVlKG[{b32gUWRCNU2ELUKzNUBk\WyuczDheEAxNjB\|IITvJFEhfU1iYX\0[ZIhOSCqcjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	Mn7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NEe1PVgoRjJ{N{S3OVk5RC:jPh?=
BP3	M2LkbGFxd3C2b4Ppd{Bie3OjeR?=	MXWxNEB2VQ>?	MX:yOEBpenN?		MlrPTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCEUEOgZ4VtdHNiYYSgNVAhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhSW6wZYjpckBXKGGwZDDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKE[DQ2OgcYV1cG:m	MnzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNEeyNlgoRjJ\|MES3NlI5RC:jPh?=
IM9	NEG4cWpCeG:ydH;zbZMh[XO\|YYm=	NYjGPYNDOTBidV2=	NV\tdYRtOjRiaILz		MkPRTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCLTUmgZ4VtdHNiYYSgNVAhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhSW6wZYjpckBXKGGwZDDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKE[DQ2OgcYV1cG:m	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB2N{KyPEc,OjNyNEeyNlg9N2F-
RS4:11	M4jDO2Fxd3C2b4Ppd{Bie3OjeR?=	MUGxNEB2VQ>?	NIPmcXEzPCCqcoO=		MXHJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFKVNEqxNUBk\WyuczDheEAyOCC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCDbn7lfIlvKFZiYX7kJJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiRlHDV{Bu\XSqb3S=	NHeyRnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C0O\|IzQCd-MkOwOFczOjh:L3G+
HCT116	MXjBdI9xfG:\|aYOgZZN{[Xl?		MYq0PEBpenN?		NH\xZnhKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDWFEyPiCyNUOrM{sh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFHucoV5cW5iVj3GTXREKHO2YXnubY5oNWKjc3XkJIZtd3diY4n0c41mfHKrYzDt[ZRpd2R?	NXywSlNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PFI{PzJpPkK2PVgzOzd{PD;hQi=>
DMS53	MkfSRZBweHSxc3nzJIF{e2G7	MnPPOUB1dyBzMDD1US=>	NVqyNGFqOTJiaILz		MXrJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKESPU{WzJINmdGy\|IHjhdoJwemmwZzDwOVMhdXW2YX70JIF{e2W\|c3XkJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHH0JFUhfG9iMUCgeW0h[W[2ZYKgNVIhcHK\|IHL5JIludXWwb3Lsc5R1cW6pIH3leIhw\A>?	Mn3TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7OEKzO\|IoRjJ4OUiyN\|czRC:jPh?=
DMS53	Mn7iSpVv[3Srb36gZZN{[Xl?	NFzNSVA2KHSxIEGwJJVO	NWDvcnNtOTJiaILz		MmX5TY5pcWKrdHnvckBw\iCEQ3ytNk9DcW1iaX70[ZJi[3Srb36gbY4hcHWvYX6gSG1UPTNiY3XscJMhcGG{Yn;ybY5oKHB3MzDteZRidnRiYYSgOUB1dyBzMDD1UUBi\nSncjCxNkBpenNiYomgbY1ufW6xcILlZ4lxcXSjdHnvckBu\XSqb3S=	NULsfVF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PFI{PzJpPkK2PVgzOzd{PD;hQi=>
DMS53	Mn71RZBweHSxc3nzJIF{e2G7	NIXDS482KHSxIEGwJJVO	NGDqT5UyOiCqcoO=		M{C0R2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iRF3TOVMh[2WubIOgbIFz[m:{aX7nJJA2OyCvdYThcpQh[XO\|ZYPz[YQh[XNiUFHSVEBkdGWjdnHn[UBifCB3IITvJFExKHWPIHHmeIVzKDF{IHjyd{BjgSCrbX31co9jdG:2dHnu[{Bu\XSqb3S=	M{O4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUiyN\|czLz5{Nkm4NlM4OjxxYU6=
DMS53	NFrVR4FCeG:ydH;zbZMh[XO\|YYm=	NXzESmd3PSC2bzCxNEB2VQ>?	MofDNVIhcHK\|		M4nCcWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iRF3TOVMh[2WubIOgbIFz[m:{aX7nJJA2OyCvdYThcpQh[XO\|ZYPz[YQh[XNiY3HzdIF{\S1\|IHPs[YF3[WenIHH0JFUhfG9iMUCgeW0h[W[2ZYKgNVIhcHK\|IHL5JIludXWwb3Lsc5R1cW6pIH3leIhw\A>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6MkO3Nkc,OjZ7OEKzO\|I9N2F-
DMS53	M3\TTWZ2dmO2aX;uJIF{e2G7	MlTkOUB1dyBzMDD1US=>	M1TNSFEzKGi{cx?=		Mmj2TY5pcWKrdHnvckBw\iCEQ3ytNk9D[XhiaX70[ZJi[3Srb36gbY4hcHWvYX6gSG1UPTNiY3XscJMhcGG{Yn;ybY5oKHB3MzDteZRidnRiYYSgOUB1dyBzMDD1UUBi\nSncjCxNkBpenNiYomgbY1ufW6xcILlZ4lxcXSjdHnvckBu\XSqb3S=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6MkO3Nkc,OjZ7OEKzO\|I9N2F-
U-2 OS	NYnUU5NleUiWUzDhd5NigQ>?				NIPzNGJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz	M4jEdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MlHFdWhVWyCjc4PhfS=>				Mn;jdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	MmXRdWhVWyCjc4PhfS=>				MkXIdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	NEHHWnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	NWS3fGtteUiWUzDhd5NigQ>?				M3vVfJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MXnxTHRUKGG\|c3H5				M2G0fZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	M2KwO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	NFfEbnZyUFSVIHHzd4F6				MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	MXHxTHRUKGG\|c3H5				MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	NYXOWYxnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	NXyzcFh1eUiWUzDhd5NigQ>?				MoPhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	MmW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	MV7xTHRUKGG\|c3H5				NX;pSHJMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	NY\pTHg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	NWD3ZVlSeUiWUzDhd5NigQ>?				NX7uNlNoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	MnzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	NIfUXXlyUFSVIHHzd4F6				MoTpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>?	NGPJeHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	M{jRfJFJXFNiYYPzZZk>				M4DHVJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	M1zwcZFJXFNiYYPzZZk>				NUC0XG5SeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	MkLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	NY\mbGdjeUiWUzDhd5NigQ>?				M13sUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	M2qxNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MXvxTHRUKGG\|c3H5				M3j1OZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	M2H3bJFJXFNiYYPzZZk>				MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM>	M4n6bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	M2XUbZFJXFNiYYPzZZk>				NIW3ZWpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{	M4O2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NELieVJyUFSVIHHzd4F6				NFvabW1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NXr0d\|RzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	NH60e4RyUFSVIHHzd4F6				NWDrN5p4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NFXRPXpyUFSVIHHzd4F6				MkHkdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	NIXW[GY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	MUPxTHRUKGG\|c3H5				M1HNe5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NVP0cZNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NFnTNphyUFSVIHHzd4F6				NFu1N\|hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	MkDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	M2nidZFJXFNiYYPzZZk>				MmiydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	M1fkOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MoCxdWhVWyCjc4PhfS=>				NXzB[3J2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	Mny3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	Mn3XdWhVWyCjc4PhfS=>				MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	NEL0[Wk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	NH;afWlyUFSVIHHzd4F6				M1iyeJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NVy5XVQ2eUiWUzDhd5NigQ>?				NV21OJZ5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NX32[XpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PARP / c-PARP / cleaved caspase 3 ; PubMed: 21393866 J Clin Invest H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. Hif-1a; PubMed: 22006676 Mol Cancer Ther Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments. γ-H2AX / p-ATM; PubMed: 21084274 Cancer Res Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.	21393866 22006676 21084274
Immunofluorescence	cytochrome C; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. Bax; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells. Bim; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. AIF; PubMed: 25034785 Cell Death Differ localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. p65 ; PubMed: 28846096 Nat Cell Biol BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.	26447615 25034785 28846096
Growth inhibition assay	Cell viability; PubMed: 22311987 J Biol Chem Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.	22311987
ELISA	IL-6 / IL-8; PubMed: 21084274 Cancer Res The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.	21084274

In vivo

In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. ^[1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. ^[2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Fluorescence polarization assays: Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research: ^[4]	- Collapse Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114 Concentrations: 0.001-10 μM Incubation Time: 48 hours Method: SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells Dosages: 20 and 30 mg/kg Administration: For intraperitoneal (i.p.) every day (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (122.93 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2%DMSO+40%PEG300+5%Tween80+53%ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download ABT-737 SDF

Molecular Weight	813.43
Formula	C₄₂H₄₅ClN₆O₅S₂
CAS No.	852808-04-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommended method about reconstitution of the compound for in vivo animal study?
Answer:
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax (BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
(R)-(-)-Gossypol acetic acid

(R)-(-)-Gossypol (AT-101) acetic acid, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. AT-101 simultaneously triggers apoptosis and a cytoprotective type of autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737